Interleukins have moved from basic immunology to the center of cancer therapy. IL-2 was the first FDA-approved cancer immunotherapy (1992), and today a new generation of engineered interleukins — IL-2 variants, IL-15 superagonists, and IL-12 fusion proteins — are driving the next wave of immuno-oncology drug development. This article reviews the key interleukins in cancer immunotherapy and the recombinant reagents researchers need to study them.
IL-2: The Founding Immunotherapy Cytokine
High-dose IL-2 (aldesleukin) induces durable complete responses in ~6-8% of metastatic melanoma and renal cell carcinoma patients. IL-2 drives expansion of effector T cells and NK cells, but also stimulates immunosuppressive regulatory T cells (Tregs) — a dual role that has prompted extensive engineering efforts. Next-generation IL-2 variants (bempegaldesleukin, nemvaleukin) preferentially activate effector T cells over Tregs through receptor bias and PEGylation. Recombinant IL-2 with verified ED50 values is essential for screening these variants in T cell proliferation assays.
IL-15: The NK Cell Powerhouse
IL-15 shares the IL-2 receptor β and γ chains but, unlike IL-2, does not expand Tregs — making it an attractive alternative for cancer immunotherapy. IL-15 superagonist complexes (N-803, ALT-803) show promising activity in bladder cancer clinical trials. Recombinant IL-15 is widely used in NK cell expansion protocols for adoptive cell therapy research.
IL-12: The Anti-Tumor Cytokine with a Delivery Problem
IL-12 promotes Th1 differentiation and IFN-γ production, but systemic toxicity has limited its clinical development. Modern approaches deliver IL-12 locally — via tumor-targeting antibodies, oncolytic viruses, or mRNA-LNPs. Researchers screening IL-12 fusion constructs need high-purity recombinant IL-12 as a reference standard and for receptor binding assays.
IL-18 and IL-21: Emerging Players
IL-18 synergizes with IL-12 to drive IFN-γ production; an engineered “decoy-resistant” IL-18 (DR-18) shows remarkable anti-tumor activity in preclinical models. IL-21 supports CD8+ T cell and NK cell function and has been explored in combination with checkpoint inhibitors.
Essential Reagents for Interleukin Immunotherapy Research
- Active interleukins with cell-based bioactivity data for functional assays
- Interleukin receptors (IL-2Rα/β/γ, IL-15Rα) for binding and SPR studies
- Low-endotoxin preparations (<1 EU/μg) for sensitive primary cell cultures
- Carrier-free formats for in vivo studies
BioCrest Sci provides 325+ recombinant interleukins covering all families discussed here, with flexible tags, expression systems, and formulations. Explore our Interleukins resource hub for detailed family guides, or request technical support for your specific immuno-oncology program.